- Home
- NYT vs LNTH Comparison
NYT vs LNTH Comparison
Compare NYT & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYT
- LNTH
- Stock Information
- Founded
- NYT 1851
- LNTH 1956
- Country
- NYT United States
- LNTH United States
- Employees
- NYT N/A
- LNTH N/A
- Industry
- NYT Newspapers/Magazines
- LNTH Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- NYT Consumer Discretionary
- LNTH Health Care
- Exchange
- NYT Nasdaq
- LNTH Nasdaq
- Market Cap
- NYT 8.6B
- LNTH 7.5B
- IPO Year
- NYT N/A
- LNTH 2015
- Fundamental
- Price
- NYT $55.45
- LNTH $80.42
- Analyst Decision
- NYT Buy
- LNTH Strong Buy
- Analyst Count
- NYT 5
- LNTH 5
- Target Price
- NYT $56.40
- LNTH $131.20
- AVG Volume (30 Days)
- NYT 1.4M
- LNTH 999.3K
- Earning Date
- NYT 08-06-2025
- LNTH 07-30-2025
- Dividend Yield
- NYT 1.26%
- LNTH N/A
- EPS Growth
- NYT 21.26
- LNTH N/A
- EPS
- NYT 1.83
- LNTH 3.53
- Revenue
- NYT $2,600,814,000.00
- LNTH $1,536,699,000.00
- Revenue This Year
- NYT $8.84
- LNTH $4.63
- Revenue Next Year
- NYT $5.89
- LNTH $9.35
- P/E Ratio
- NYT $31.20
- LNTH $22.77
- Revenue Growth
- NYT 6.90
- LNTH 12.53
- 52 Week Low
- NYT $44.83
- LNTH $73.11
- 52 Week High
- NYT $58.16
- LNTH $126.89
- Technical
- Relative Strength Index (RSI)
- NYT 66.58
- LNTH 48.55
- Support Level
- NYT $54.87
- LNTH $78.41
- Resistance Level
- NYT $55.06
- LNTH $82.50
- Average True Range (ATR)
- NYT 0.97
- LNTH 2.17
- MACD
- NYT 0.11
- LNTH 0.41
- Stochastic Oscillator
- NYT 95.14
- LNTH 66.23
About NYT New York Times Company (The)
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as NYTimes and various smartphone applications. The company has two segments: New York Times Group and The Athletic. The company generates the majority of its revenue from the NYTG segment. The NYTG and The Athletic segments derive revenue from subscriptions, Advertising, and others, where the majority source of revenue for both segments is subscription.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.